MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- LUPIN LIMITED (pharmaceuticals)
- LUPIN LIMITED Financial Data
Lupin Ltd Fact Sheet 
(LUPL)
Here is the latest financial fact sheet of Lupin Ltd. For more details, see the Lupin Ltd quarterly results and Lupin Ltd share price and chart. For a sector overview, read our pharmaceuticals sector report.
LUPIN Price History
| % ch | % | -0.7 |
| No. of shares | m | 451.14 |
| % ch week | % | -3.4 |
| % ch 1-mth | % | -7.2 |
| % ch 12-mth | % | -22.0 |
| 52 week H/L | Rs | 986.0/704.8 |
LUPIN Financials
| No. of Mths Year Ending |
12 Mar-14* |
12 Mar-15* |
12 Mar-16* |
12 Mar-17* |
12 Mar-18* |
5-Yr Chart Click to enlarge
|
|---|
| LUPIN EQUITY SHARE DATA | |||||||
|---|---|---|---|---|---|---|---|
| High | Rs | 1,003 | 2,037 | 2,127 | 1,750 | 1,465 | |
| Low | Rs | 606 | 904 | 1,294 | 1,384 | 727 | |
| Sales per share (Unadj.) | Rs | 251.7 | 280.3 | 316.4 | 387.4 | 349.6 | |
| Earnings per share (Unadj.) | Rs | 41.0 | 53.5 | 50.2 | 56.6 | 5.6 | |
| Diluted earnings per share | Rs | 40.7 | 53.3 | 50.1 | 56.7 | 5.6 | |
| Cash flow per share (Unadj.) | Rs | 46.8 | 63.1 | 61.0 | 76.8 | 29.6 | |
| Dividends per share (Unadj.) | Rs | 6.00 | 7.50 | 7.50 | 7.50 | 5.00 | |
| Adj. dividends per share | Rs | 5.96 | 7.47 | 7.49 | 7.51 | 5.01 | |
| Dividend yield (eoy) | % | 0.7 | 0.5 | 0.4 | 0.5 | 0.5 | |
| Book value per share (Unadj.) | Rs | 154.6 | 204.1 | 247.8 | 298.9 | 300.3 | |
| Adj. book value per share | Rs | 153.6 | 203.3 | 247.4 | 299.2 | 301.0 | |
| Shares outstanding (eoy) | m | 448.38 | 449.49 | 450.58 | 451.58 | 452.08 | |
| Bonus/Rights/Conversions | ESOP | ESOP | - | ESOPS | ESOPS | ||
| Price / Sales ratio | x | 3.2 | 5.2 | 5.4 | 4.0 | 3.1 | |
| Avg P/E ratio | x | 19.6 | 27.5 | 34.1 | 27.7 | 197.2 | |
| P/CF ratio (eoy) | x | 17.2 | 23.3 | 28.0 | 20.4 | 37.1 | |
| Price / Book Value ratio | x | 5.2 | 7.2 | 6.9 | 5.2 | 3.6 | |
| Dividend payout | % | 14.6 | 14.0 | 14.9 | 13.2 | 90.0 | |
| Avg Mkt Cap | Rs m | 360,767 | 660,975 | 770,740 | 707,513 | 495,502 | |
| No. of employees | `000 | NA | 14.2 | 16.4 | 16.8 | 17.0 | |
| Total wages/salary | Rs m | 14,647 | 17,473 | 21,416 | 28,495 | 28,647 | |
| Avg. sales/employee | Rs Th | NM | 8,874.3 | 8,718.5 | 10,418.3 | 9,273.6 | |
| Avg. wages/employee | Rs Th | NM | 1,230.7 | 1,309.8 | 1,697.0 | 1,681.0 | |
| Avg. net profit/employee | Rs Th | NM | 1,692.7 | 1,382.6 | 1,523.0 | 147.4 | |
| LUPIN INCOME DATA | |||||||
|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 112,866 | 125,997 | 142,555 | 174,943 | 158,042 | |
| Other income | Rs m | 1,165 | 2,398 | 1,852 | 1,065 | 1,504 | |
| Total revenues | Rs m | 114,031 | 128,395 | 144,407 | 176,008 | 159,545 | |
| Gross profit | Rs m | 30,028 | 36,196 | 36,854 | 44,931 | 31,475 | |
| Depreciation | Rs m | 2,610 | 4,347 | 4,871 | 9,122 | 10,859 | |
| Interest | Rs m | 267 | 98 | 595 | 1,525 | 2,044 | |
| Profit before tax | Rs m | 28,317 | 34,148 | 33,239 | 35,349 | 20,076 | |
| Minority Interest | Rs m | -331 | -412 | -88 | -72 | -71 | |
| Prior Period Items | Rs m | 0 | 0 | 49 | 83 | 35 | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | -14,644 | |
| Tax | Rs m | 9,622 | 9,704 | 10,593 | 9,785 | 2,885 | |
| Profit after tax | Rs m | 18,364 | 24,032 | 22,607 | 25,575 | 2,513 | |
| Gross profit margin | % | 26.6 | 28.7 | 25.9 | 25.7 | 19.9 | |
| Effective tax rate | % | 34.0 | 28.4 | 31.9 | 27.7 | 14.4 | |
| Net profit margin | % | 16.3 | 19.1 | 15.9 | 14.6 | 1.6 | |
| LUPIN BALANCE SHEET DATA | |||||||
|---|---|---|---|---|---|---|---|
| Current assets | Rs m | 61,005 | 78,040 | 98,874 | 119,529 | 122,095 | |
| Current liabilities | Rs m | 26,296 | 34,633 | 50,612 | 61,206 | 50,956 | |
| Net working cap to sales | % | 30.8 | 34.5 | 33.9 | 33.3 | 45.0 | |
| Current ratio | x | 2.3 | 2.3 | 2.0 | 2.0 | 2.4 | |
| Inventory Days | Days | 69 | 73 | 84 | 76 | 85 | |
| Debtors Days | Days | 80 | 77 | 116 | 90 | 120 | |
| Net fixed assets | Rs m | 30,019 | 49,213 | 114,194 | 131,660 | 129,876 | |
| Share capital | Rs m | 897 | 899 | 901 | 903 | 904 | |
| "Free" reserves | Rs m | 67,922 | 90,833 | 110,733 | 134,073 | 134,866 | |
| Net worth | Rs m | 69,316 | 91,732 | 111,634 | 134,976 | 135,771 | |
| Long term debt | Rs m | 1,510 | 1,018 | 53,739 | 56,478 | 64,245 | |
| Total assets | Rs m | 102,060 | 132,610 | 226,249 | 266,073 | 263,054 | |
| Interest coverage | x | 107.3 | 349.1 | 56.9 | 24.2 | 10.8 | |
| Debt to equity ratio | x | 0 | 0 | 0.5 | 0.4 | 0.5 | |
| Sales to assets ratio | x | 1.1 | 1.0 | 0.6 | 0.7 | 0.6 | |
| Return on assets | % | 18.3 | 18.2 | 10.3 | 10.2 | 1.7 | |
| Return on equity | % | 26.5 | 26.2 | 20.3 | 18.9 | 1.9 | |
| Return on capital | % | 39.9 | 36.5 | 20.4 | 19.3 | 3.7 | |
| Exports to sales | % | 50.7 | 46.4 | 47.2 | 0 | 0 | |
| Imports to sales | % | 8.6 | 8.8 | 7.2 | 0 | 0 | |
| Exports (fob) | Rs m | 57,177 | 58,482 | 67,244 | 0 | 0 | |
| Imports (cif) | Rs m | 9,654 | 11,057 | 10,199 | 0 | 0 | |
| Fx inflow | Rs m | 63,076 | 62,593 | 71,405 | 81,885 | 53,141 | |
| Fx outflow | Rs m | 16,480 | 16,592 | 17,807 | 21,506 | 19,335 | |
| Net fx | Rs m | 46,596 | 46,001 | 53,598 | 60,378 | 33,807 | |
| LUPIN CASH FLOW | |||||||
|---|---|---|---|---|---|---|---|
| From Operations | Rs m | 20,039 | 27,331 | -3,824 | 41,135 | 17,512 | |
| From Investments | Rs m | -8,585 | -10,545 | -69,617 | -25,274 | -14,073 | |
| From Financial Activity | Rs m | -8,571 | -1,969 | 58,364 | 4,332 | -14,921 | |
| Net Cashflow | Rs m | 2,883 | 14,817 | -15,077 | 20,193 | -11,482 | |
Share Holding
|
Company Information
|
|||||||||||||||||||||||||||||||||||||||||
| CHM: D. B. Gupta | COMP SEC: R. V. Satam | YEAR OF INC: 1983 | BSE CODE: 500257 | FV (Rs): 2 | DIV YIELD (%): 0.7 |
Read: LUPIN LTD 2017-18 Annual Report Analysis
More Pharmaceuticals Company Fact Sheets: GSK PHARMA FDC LTD. ASTRAZENECA PHARMA MERCK FRESENIUS KABI ONCO.
Compare LUPIN With: GSK PHARMA FDC LTD. ASTRAZENECA PHARMA MERCK FRESENIUS KABI ONCO.
Compare LUPIN With: ACTAVIS (US) MYLAN (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
|
| |
Today's Market
Indian Indices Turn Volatile; Yes Bank Slips 5%(12:30 pm)
Share markets in India are presently trading marginally higher. Sectoral indices are trading on a mixed note with stocks in the consumer durables sector.
Views on news
LUPIN Announces Quarterly Results (4QFY19); Net Profit Down 1.5% (Quarterly Result Update)
May 17, 2019 | Updated on May 17, 2019For the quarter ended March 2019, LUPIN has posted a net profit of Rs 3 bn (down 1.5% YoY). Sales on the other hand came in at Rs 44 bn (up 77.8% YoY). Read on for a complete analysis of LUPIN's quarterly results.
LUPIN LTD Announces Quarterly Results (3QFY19); Net Profit Down 149.7% (Quarterly Result Update)
Feb 13, 2019 | Updated on Feb 13, 2019For the quarter ended December 2018, LUPIN LTD has posted a net profit of Rs 2 bn (down 149.7% YoY). Sales on the other hand came in at Rs 45 bn (up 78.0% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.
LUPIN LTD 2017-18 Annual Report Analysis (Annual Result Update)
Aug 16, 2018 | Updated on Aug 16, 2018Here's an analysis of the annual report of LUPIN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of LUPIN LTD. Also includes updates on the valuation of LUPIN LTD.
Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)
Feb 9, 2018Price erosion in generic US drugs continues but seems to be bottoming out.
Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)
Nov 2, 2017Domestic markets registers robust growth in the quarter
More Views on NewsMost Popular
7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)
Jun 13, 2019We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?
The Great Indian NBFC Bubble Has Burst but I Will Still Recommend These Safe NBFCs(The 5 Minute Wrapup)
Jun 11, 2019One chart that predicted the NBFC crisis back in 2016.
Just One Stock Made Buffett Billions - And Can Make You Crores(Profit Hunter)
Jun 6, 2019Coca Cola is arguably one of Warren Buffet's best stock picks. But did you know that small investors picked up the stock five decades before Buffet? Read on...
Kenneth Andrade Would Like Our Real Estate Stock Recommendation with Triple Digit Upside(The 5 Minute Wrapup)
Jun 12, 2019This real estate stock recommended in Smart Money Secrets offers the most favourable upside potential.
Why Modi 2.0 Will Be Great for These 7 Stocks(Profit Hunter)
Jun 10, 2019The government's focus on Infra, electricity, water for all will be the key factors for Sensex 1,00,000.
More|
| |
TRACK LUPIN
- Track your investment in LUPIN with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON LUPIN
LUPIN - DR. DATSONS LABS COMPARISON
COMPARE LUPIN WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.